Prostate cancer Flashcards

1
Q

What is prostate cancer?

A

Prostate cancer is a common condition with up to 30,000 men diagnosed each year in the UK, and up to 9,000 men die from it annually.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the symptoms of early prostate cancer?

A

Early prostate cancers have few symptoms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What symptoms may indicate metastatic disease?

A

Metastatic disease may present as bone pain.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What symptoms may indicate locally advanced prostate cancer?

A

Locally advanced disease may present as pelvic pain or with urinary symptoms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What tests are used for diagnosing prostate cancer?

A

Diagnosis includes PSA measurement, digital rectal examination, transrectal ultrasound (with or without biopsy), and MRI/CT and bone scan for staging.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the normal upper limit for PSA?

A

The normal upper limit for PSA is 4 ng/ml.

False positives may occur due to prostatitis, UTI, BPH, or vigorous DRE.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What PSA percentage suggests cancer?

A

Values of <20% for the percentage of free to total PSA are suggestive of cancer, and a biopsy is advised.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the most common type of prostate cancer?

A

95% of prostate cancers are adenocarcinomas.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the Gleason grading system?

A

The Gleason grading system awards two grades (1-5) to the most dominant and second most dominant cancer grades, with the sum giving the Gleason score.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the significance of the Gleason score?

A

A Gleason score of 2 indicates the best prognosis, while a score of 10 indicates the worst.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How does prostate cancer typically spread?

A

Lymphatic spread occurs first to the obturator nodes, and local extra prostatic spread to the seminal vesicles is associated with distant disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the treatment options for prostate cancer?

A

Treatment options include watchful waiting, radiotherapy, surgery (radical prostatectomy), and hormonal therapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the purpose of watchful waiting?

A

Watchful waiting is suitable for elderly patients with multiple co-morbidities and a low Gleason score.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the potential side effects of surgery for prostate cancer?

A

Erectile dysfunction is a common side effect of radical prostatectomy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What does hormonal therapy for prostate cancer involve?

A

Hormonal therapy may involve bilateral orchidectomy or pharmacological alternatives like LHRH analogues and anti-androgens.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What does NICE recommend for low-risk prostate cancer patients?

A

NICE suggests active surveillance for low-risk men, particularly those with specific clinical and biopsy criteria.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What criteria must candidates for active surveillance meet?

A

Candidates should have had at least 10 biopsy cores taken and at least one re-biopsy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What should be done if disease progression is observed in active surveillance?

A

If disease progression is observed, radical treatment should be offered.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the most common cancer in adult males in the UK?

A

Prostate cancer is now the most common cancer in adult males in the UK.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the second most common cause of cancer death in men after lung cancer?

A

Prostate cancer is the second most common cause of death due to cancer in men after lung cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are the risk factors for prostate cancer?

A

Risk factors include increasing age, obesity, Afro-Caribbean ethnicity, and family history.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What percentage of prostate cancer cases have a strong family history?

A

Around 5-10% of cases have a strong family history.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Is localized prostate cancer often symptomatic?

A

Localized prostate cancer is often asymptomatic.

24
Q

Why are localized prostate cancers often asymptomatic?

A

Cancers tend to develop in the periphery of the prostate and hence don’t cause obstructive symptoms early on.

25
Q

What are possible features of localized prostate cancer?

A

Possible features include bladder outlet obstruction, haematuria, haematospermia, and pain in the back, perineal, or testicular areas.

26
Q

What symptoms may indicate bladder outlet obstruction?

A

Symptoms may include hesitancy and urinary retention.

27
Q

What findings might be observed during a digital rectal examination for prostate cancer?

A

Asymmetrical, hard, nodular enlargement with loss of median sulcus.

28
Q

What was the traditional investigation for suspected prostate cancer?

A

The traditional investigation was a transrectal ultrasound-guided (TRUS) biopsy.

29
Q

What do recent NICE guidelines recommend for suspected prostate cancer?

A

Recent NICE guidelines advocate the increasing use of multiparametric MRI as a first-line investigation.

30
Q

What are the complications of TRUS biopsy?

A

Complications include:
- Sepsis: 1% of cases
- Pain: lasting >= 2 weeks in 15% and severe in 7%
- Fever: 5%
- Haematuria and rectal bleeding.

31
Q

What is the first-line investigation for clinically localised prostate cancer?

A

Multiparametric MRI is now the first-line investigation.

32
Q

How are the results of multiparametric MRI reported?

A

The results are reported using a 5-point Likert scale.

33
Q

What is the recommendation if the Likert scale is >=3?

A

If the Likert scale is >=3, a multiparametric MRI-influenced prostate biopsy is offered.

34
Q

What should be discussed if the Likert scale is 1-2?

A

If the Likert scale is 1-2, NICE recommends discussing with the patient the pros and cons of having a biopsy.

35
Q

What was the traditional investigation for suspected prostate cancer?

A

The traditional investigation was a transrectal ultrasound-guided (TRUS) biopsy.

36
Q

What do recent NICE guidelines recommend for suspected prostate cancer?

A

Recent NICE guidelines advocate the increasing use of multiparametric MRI as a first-line investigation.

37
Q

What are the complications of TRUS biopsy?

A

Complications include:
- Sepsis: 1% of cases
- Pain: lasting >= 2 weeks in 15% and severe in 7%
- Fever: 5%
- Haematuria and rectal bleeding.

38
Q

What is the first-line investigation for clinically localised prostate cancer?

A

Multiparametric MRI is now the first-line investigation.

39
Q

How are the results of multiparametric MRI reported?

A

The results are reported using a 5-point Likert scale.

40
Q

What is the recommendation if the Likert scale is >=3?

A

If the Likert scale is >=3, a multiparametric MRI-influenced prostate biopsy is offered.

41
Q

What should be discussed if the Likert scale is 1-2?

A

If the Likert scale is 1-2, NICE recommends discussing with the patient the pros and cons of having a biopsy.

42
Q

What are the treatment options for localized prostate cancer (T1/T2)?

A

Treatment depends on life expectancy and patient choice. Options include: conservative: active monitoring & watchful waiting, radical prostatectomy, radiotherapy: external beam and brachytherapy.

43
Q

What are the treatment options for localized advanced prostate cancer (T3/T4)?

A

Options include: hormonal therapy, radical prostatectomy (with erectile dysfunction as a common complication), radiotherapy (external beam and brachytherapy).

Patients may develop proctitis and are also at increased risk of bladder, colon, and rectal cancer following radiotherapy for prostate cancer.

44
Q

What is one of the key aims of treating advanced prostate cancer?

A

One of the key aims is reducing androgen levels. A combination of approaches is often used.

45
Q

What is GnRH agonist therapy?

A

GnRH agonists, such as Goserelin (Zoladex), initially cause a rise in testosterone levels for 2-3 weeks before falling to castration levels due to overstimulation and disruption of hormonal feedback systems.

Initial therapy is often covered with an anti-androgen to prevent a rise in testosterone - ‘tumour flare’.

46
Q

What are some examples of anti-androgen therapies?

A

Examples include bicalutamide (non-steroidal anti-androgen) and cyproterone acetate (steroidal anti-androgen).

Cyproterone acetate is used less commonly since the introduction of non-steroidal anti-androgens.

47
Q

What is abiraterone used for?

A

Abiraterone is an androgen synthesis inhibitor used for the treatment of hormone-relapsed metastatic prostate cancer in patients who have no or mild symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated.

48
Q

What is bilateral orchidectomy?

A

Bilateral orchidectomy is used to rapidly reduce testosterone levels.

49
Q

What is PSA?

A

Prostate specific antigen (PSA) is a serine protease enzyme produced by normal and malignant prostate epithelial cells.

50
Q

What is the controversy surrounding PSA testing?

A

PSA testing has become an important tumour marker, but much controversy still exists regarding its usefulness as a screening tool.

51
Q

When should PSA testing be considered?

A

PSA testing should be considered in men with suspected prostate cancer and offered to men older than 50 years of age who request a PSA test.

52
Q

What are the age-specific PSA thresholds for referral?

A

Age-specific PSA thresholds are as follows:
- < 40: Use clinical judgement
- 40–49: > 2.5 ng/ml
- 50–59: > 3.5 ng/ml
- 60–69: > 4.5 ng/ml
- 70–79: > 6.5 ng/ml
- > 79: Use clinical judgement.

53
Q

What should be done if a patient’s PSA level is above the threshold for their age?

A

Patients with a PSA above the threshold should be referred on the suspected cancer pathway referral for an appointment within 2 weeks.

54
Q

What can raise PSA levels?

A

PSA levels may be raised by benign prostatic hyperplasia (BPH), prostatitis, urinary tract infection, ejaculation, vigorous exercise, urinary retention, and instrumentation of the urinary tract.

55
Q

What is the recommendation regarding PSA testing after treatment for prostatitis or urinary tract infection?

A

NICE recommends postponing the PSA test for at least 6 weeks after treatment.

56
Q

What are the limitations of PSA testing?

A

PSA testing has poor specificity and sensitivity; around 33% of men with a PSA of 4-10 ng/ml will have prostate cancer, and around 15% with prostate cancer have a normal PSA.

57
Q

What methods are used to add meaning to PSA levels?

A

Various methods include age-adjusted upper limits and monitoring change in PSA level with time (PSA velocity or PSA doubling time).